In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk A/S

https://www.novonordisk.com/

Latest From Novo Nordisk A/S

Acceleron To Be Next M&A Target With Rumored $11bn Deal

The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

HHS Weighs Fines For 340B Restrictions; AstraZeneca Says They Could Reach $530M Per Month

US government moves ahead with enforcement action while several court decisions remain pending on the viability of its interpretation of the law governing the 340B outpatient drug discount program. Underscoring industry’s confidence in its opposing view, Merck & Co. recently joined the companies that are restricting discounts to contract pharmacies.

Reimbursement Legal Issues

Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?

Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.

Gene Therapy Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Carbometrics
    • Corvidia Therapeutics
    • Neose Technologies, Inc.
    • Novo Holdings A/S
    • Novo Nordisk Pharmaceuticals, Inc.
    • Pharmaero Aps
    • Xellia Pharmaceuticals ApS
    • Ziylo Ltd
UsernamePublicRestriction

Register